3 Stocks Raising The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 104 points (-0.6%) at 17,824 as of Wednesday, May 6, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 986 issues advancing vs. 2,035 declining with 119 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Herbalife ( HLF), up 20.3%, Usana Health ( USNA), up 19.8%, Incyte ( INCY), up 2.2%, Sanofi ( SNY), up 1.1% and GlaxoSmithKline ( GSK), up 0.8%. On the negative front, top decliners within the industry include Mylan ( MYL), down 2.7%, Teva Pharmaceutical Industries ( TEVA), down 1.6%, Pfizer ( PFE), down 1.2% and Gilead ( GILD), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Vertex Pharmaceuticals is up $1.87 (1.5%) to $124.02 on average volume. Thus far, 631,285 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $122.09-$125.16 after having opened the day at $122.61 as compared to the previous trading day's close of $122.15.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $30.8 billion and is part of the health care sector. Shares are up 6.3% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $8.89 (1.9%) to $474.39 on average volume. Thus far, 406,737 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 852,000 shares. The stock has ranged in price between $466.18-$478.00 after having opened the day at $469.16 as compared to the previous trading day's close of $465.50.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $48.0 billion and is part of the health care sector. Shares are up 15.6% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Regeneron Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Celgene ( CELG) is up $0.60 (0.6%) to $108.14 on average volume. Thus far, 2.7 million shares of Celgene exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $106.45-$108.99 after having opened the day at $108.49 as compared to the previous trading day's close of $107.54.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $87.2 billion and is part of the health care sector. Shares are down 1.8% year-to-date as of the close of trading on Tuesday. Currently there are 14 analysts who rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Celgene Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting